NO20022525L - Farmasöytiske formuleringer inneholdende zolmitriptan - Google Patents

Farmasöytiske formuleringer inneholdende zolmitriptan

Info

Publication number
NO20022525L
NO20022525L NO20022525A NO20022525A NO20022525L NO 20022525 L NO20022525 L NO 20022525L NO 20022525 A NO20022525 A NO 20022525A NO 20022525 A NO20022525 A NO 20022525A NO 20022525 L NO20022525 L NO 20022525L
Authority
NO
Norway
Prior art keywords
pharmaceutical formulations
formulations containing
zolmitriptan
containing zolmitriptan
formulation
Prior art date
Application number
NO20022525A
Other languages
English (en)
Other versions
NO20022525D0 (no
NO322119B1 (no
Inventor
Alan Roy Dearn
Sarah Louise Williamson
Simon John Summers
Trevor John Coomber
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10865629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20022525(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20022525D0 publication Critical patent/NO20022525D0/no
Publication of NO20022525L publication Critical patent/NO20022525L/no
Publication of NO322119B1 publication Critical patent/NO322119B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20022525A 1999-12-03 2002-05-28 Farmasøytiske formuleringer inneholdende zolmitriptan for intranasal administrering NO322119B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9928578.5A GB9928578D0 (en) 1999-12-03 1999-12-03 Pharmaceutical formulations
PCT/GB2000/004528 WO2001039772A1 (en) 1999-12-03 2000-11-28 Pharmaceutical formulations containing zolmitriptan

Publications (3)

Publication Number Publication Date
NO20022525D0 NO20022525D0 (no) 2002-05-28
NO20022525L true NO20022525L (no) 2002-05-28
NO322119B1 NO322119B1 (no) 2006-08-14

Family

ID=10865629

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022525A NO322119B1 (no) 1999-12-03 2002-05-28 Farmasøytiske formuleringer inneholdende zolmitriptan for intranasal administrering

Country Status (28)

Country Link
US (2) US6750237B1 (no)
EP (1) EP1237551B1 (no)
JP (1) JP2003515559A (no)
KR (1) KR100670092B1 (no)
CN (1) CN1222287C (no)
AT (1) ATE291914T1 (no)
AU (1) AU778092B2 (no)
BR (1) BRPI0016138B8 (no)
CA (1) CA2392050C (no)
CZ (1) CZ301528B6 (no)
DE (1) DE60019162T2 (no)
EE (1) EE05305B1 (no)
ES (1) ES2236001T3 (no)
GB (2) GB9928578D0 (no)
HK (3) HK1048442B (no)
HU (1) HU229458B1 (no)
IL (2) IL149578A0 (no)
IS (1) IS2135B (no)
MX (1) MXPA02005319A (no)
NO (1) NO322119B1 (no)
NZ (1) NZ518862A (no)
PL (1) PL200679B1 (no)
PT (1) PT1237551E (no)
RU (1) RU2255736C2 (no)
SK (1) SK287228B6 (no)
UA (1) UA75059C2 (no)
WO (1) WO2001039772A1 (no)
ZA (1) ZA200203704B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
US20050256182A1 (en) * 2004-05-11 2005-11-17 Sutter Diane E Formulations of anti-pain agents and methods of using the same
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
JP2008500288A (ja) * 2004-05-28 2008-01-10 イメイジノット ピーティーワイ エルティーディー 経口治療用化合物の供給系
WO2006055964A2 (en) * 2004-11-19 2006-05-26 Teva Pharmaceutical Industries Ltd. Zolmitriptan crystal forms
CN100341504C (zh) * 2004-12-01 2007-10-10 鲁南制药集团股份有限公司 佐米曲普坦速释制剂
AU2006317530B2 (en) * 2005-11-28 2011-09-01 Imaginot Pty Ltd Oral therapeutic compound delivery system
WO2008016678A2 (en) * 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
ATE502921T1 (de) * 2006-10-19 2011-04-15 Auspex Pharmaceuticals Inc Substituierte indole
KR101517415B1 (ko) * 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
WO2012048710A1 (en) 2010-10-15 2012-04-19 Concit Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
JP6121734B2 (ja) * 2012-02-09 2017-04-26 久光製薬株式会社 マイクロニードル用ゾルミトリプタン含有コーティング組成物及びマイクロニードルデバイス
RU2670272C2 (ru) 2012-04-18 2018-10-22 Контера Фарма Апс Пероральная фармацевтическая композиция, подходящая для повышения эффективности лечения двигательных нарушений
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
KR101624049B1 (ko) 2014-10-29 2016-05-24 연세대학교 산학협력단 사카린을 이용한 용해도를 증가시킨 약제학적 조성물
EP3310360B1 (en) * 2015-06-19 2024-03-27 Beijing Artivila BioPharma Co. Ltd. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
WO2017122161A1 (en) 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
KR102443161B1 (ko) 2016-07-11 2022-09-14 콘테라 파르마 에이/에스 아침 운동 불능을 치료하기 위한 박동성 약물 전달 시스템
WO2019126766A1 (en) * 2017-12-21 2019-06-27 Taiwan Liposome Co., Ltd. Sustained-release triptan compositions and method of use the same through subdermal route or the like
US20210322343A1 (en) 2020-04-15 2021-10-21 Farzana Shaheen Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU646871B2 (en) * 1990-06-07 1994-03-10 Astrazeneca Uk Limited Therapeutic heterocyclic compounds
IL127956A0 (en) 1996-07-11 1999-11-30 Farmarc Nederland Bv Inclusion complex containing indole selective serotonin agonist
GB2315673A (en) * 1996-08-01 1998-02-11 Merck & Co Inc Treatment of migraine
DK1014943T3 (da) 1997-02-05 2002-10-14 Jago Res Ag Medicinske aerosolformuleringer
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
AU1715701A (en) 2001-06-12
CZ301528B6 (cs) 2010-04-07
BR0016138A (pt) 2002-08-06
NZ518862A (en) 2004-02-27
HK1048445A1 (en) 2003-04-04
GB0214845D0 (en) 2002-08-07
EP1237551B1 (en) 2005-03-30
IL149578A (en) 2008-04-13
ES2236001T3 (es) 2005-07-16
WO2001039772A1 (en) 2001-06-07
EE200200283A (et) 2003-06-16
JP2003515559A (ja) 2003-05-07
BRPI0016138B8 (pt) 2021-05-25
IS6394A (is) 2002-05-24
GB2373726A (en) 2002-10-02
HUP0203597A3 (en) 2005-07-28
DE60019162D1 (de) 2005-05-04
US20040214899A1 (en) 2004-10-28
SK7532002A3 (en) 2002-12-03
KR100670092B1 (ko) 2007-01-17
DE60019162T2 (de) 2006-02-02
GB2373726B (en) 2004-10-20
PL200679B1 (pl) 2009-01-30
NO20022525D0 (no) 2002-05-28
UA75059C2 (uk) 2006-03-15
HK1048442A1 (en) 2003-04-04
HU229458B1 (en) 2013-12-30
HUP0203597A2 (hu) 2003-02-28
RU2255736C2 (ru) 2005-07-10
RU2002117649A (ru) 2004-01-27
CN1222287C (zh) 2005-10-12
PT1237551E (pt) 2005-07-29
GB9928578D0 (en) 2000-02-02
HK1048442B (zh) 2005-05-13
IS2135B (is) 2006-08-15
EP1237551A1 (en) 2002-09-11
IL149578A0 (en) 2002-11-10
KR20020058051A (ko) 2002-07-12
CA2392050C (en) 2009-11-24
AU778092B2 (en) 2004-11-18
CN1402636A (zh) 2003-03-12
HK1048445B (zh) 2005-08-26
BR0016138B1 (pt) 2013-09-10
US6750237B1 (en) 2004-06-15
HK1053430A1 (en) 2003-10-24
US7220767B2 (en) 2007-05-22
PL357597A1 (en) 2004-07-26
MXPA02005319A (es) 2002-12-06
CZ20021901A3 (cs) 2002-11-13
ZA200203704B (en) 2003-10-29
EE05305B1 (et) 2010-06-15
ATE291914T1 (de) 2005-04-15
SK287228B6 (sk) 2010-03-08
CA2392050A1 (en) 2001-06-07
NO322119B1 (no) 2006-08-14

Similar Documents

Publication Publication Date Title
NO20022525D0 (no) Farmasöytiske formuleringer inneholdende zolmitriptan
GB0005251D0 (en) Therapeutic compounds
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
ID27504A (id) Formulasi oral baru
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
HUP0301349A2 (hu) IL-11-tartalmú készítmények
NO20004419L (no) Ny anvendelse
DK1112060T3 (da) Doseringsform anvendende flydende formulering
DE60112756D1 (de) Racecadotril enthaltende trockene pulverformulierung
RS50089B (sr) Suspenzija ziprasidona
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
ATE360428T1 (de) Analgetisches arzneimittel
SE0001916D0 (sv) Novel formulation
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
ES2159479A1 (es) Nuevos indazoles como inhibidores de la ciclooxigenasa-ii
TR200000916T2 (tr) İkameli piperidin türevleri.
ATE247976T1 (de) 10-formyltetrahydrofolate dehydrogenase als therapeutischen mittel
UA38889A (uk) Лікувальний засіб "ліварекс" на основі диметоксіуреїдофосфорної кислоти

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GRUENENTHAL GMBH, DE

MK1K Patent expired